Abstract:e13529 Background: Thymomas and thymic carcinomas which uniformly known as thymic epithelial tumors (TETs) are rare intrathoracic malignancies and a limited studies have been reported addressing the molecular biology and immune discrepancy. The main purpose of this study was to depict the genomic and transcriptomic landscape of thymomas and thymic carcinomas, as well as elucidate the differentiated immune microenvironment. Methods: Totally 15 thymomas and 7 thymic carcinomas patients were enrolled from January 2014 to July 2018. Treatment-naïve tissue samples were collected, and we also obtained matched peripheral blood mononucleocytes as negative control. DNA and RNA were co-extracted and performed with whole exon and transcriptome sequencing. The immune cell infiltration scores were estimated using ssGSEA algorithm. Results: Exome sequencing revealed that GTF2I mutation occurred in all of type A thymomas but was absent in the aggressive subtypes. The median tumor mutation burden of thymomas was 0.12/Mb, significantly lower than thymic carcinomas (median: 1.02/Mb, p = 0.001). Copy number variation was more common in thymic carcinomas than thymomas (83.3% vs 9.1%, p = 0.005). Top mutational signatures enriched in both thymomas and thymic carcinomas included age and Aristolochic acid exposure, while the APOBEC signature was more common in thymomas than thymic carcinomas (81.8% vs 16.7%, p = 0.03). As a confirmed immune escape event, loss of heterozygosity of human leukocyte antigen was identified in 9.1% of thymomas and 50% of thymic carcinomas. Via unsupervised clustering of immune infiltration, all tissue samples were classified into high- and low-infiltration subgroups. Remarkably, up to 71.4% of samples from thymic carcinomas and only 6.7% of samples from thymomas were defined as low immune cell infiltration. In consideration of specific immune cell types, macrophage ( p = 0.01) and neutrophil ( p = 0.02) were enriched in thymic carcinomas while CD56+ NK cell ( p = 0.005) was enriched in thymomas, indicating the evidential discrepancy about immune cell infiltration between two subtypes of TETs. Conclusions: This study elucidated the molecular and immune microenvironment discrepancy between two subtypes of TETs. From molecular perspective, thymomas and thymic carcinomas are entirely different diseases with different etiology and characterized by distinct immune infiltration, and thus should be managed with disparate therapeutic strategies. Findings in this study may also be useful in future targets development and exploration of immunotherapies in TETs.

Clinical significances of D2-40 expression in thymic epithelial tumors

Correlation between the Expression of PD-L1 and Clinicopathological Features in Patients with Thymic Epithelial Tumors

The Expression of PD-L1 and B7-H4 in Thymic Epithelial Tumor and Its Relationship With Tumor Immune-Infiltrating Cells

The Impact of PD-L1, TGF-β Expression and Tumor-Infiltrating CD8+ T Cells on Clinical Outcome of Patients with Advanced Thymic Epithelial Tumors

Expressions of D2-40 in Pancreatic Carcinoma and Their Clinical Significance by Tissue Microarray Methods

Comprehensive study of clinicopathological and immune cell infiltration and lactate dehydrogenase expression in patients with thymic epithelial tumours

P1.14-28 Frequent Genetic Alterations and Their Clinical Significance in Patients with Thymic Epithelial Tumors

Expression of vascular endothelial growth factor receptor in thymic epithelial tumors

The Efficacy and Safety of Immunotherapy in Thymic Epithelial Tumors: More Effective, More Risky: a Systematic Review

Clinical Significance of Lymph Vessel Density Marked by D2-40 in Laryngeal Squamous Cell Carcinomas

Transcriptomic and Mutational Analysis Discovering Distinct Molecular Characteristics Among Chinese Thymic Epithelial Tumor Patients

Deciphering tissue-based proteome signatures revealed novel subtyping and prognostic markers for thymic epithelial tumors

Multi-slice CT Finding of Thymic Epithelial Tumors and Its Correlation with WHO Histopathologic Classification

[Prognostic Factors for Thymic Epithelial Tumor: a Retrospective Study of 137 Cases].

Expression and Clinical Value of P53, CD117 and CD44v5 in Thymus Epithelial Tumor

Significance of tumor mutation burden and immune infiltration in thymic epithelial tumors

Expression and Prognostic Value of MCM2 in type B thymomas

Detection of D2-40-positive lymphatic microvessel density and its clinical significance in lung cancer

[Clinicopathological Significance of Grading on Thymic Epithelial Tumors].

[Expression of CD20 in Thymomas and Its Clinical Implication].

Distinct Genomic And Immune Microenvironment Between Thymomas And Thymic Carcinomas.